General Information of Drug (ID: DM10Z5W)

Drug Name
Il-8((3-73))K11R Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DM10Z5W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [2]
Reparixin DMVBA7I Pancreatic islet transplantation failure NE84 Phase 3 [2]
SCH-527123 DMPUAOE Chronic obstructive pulmonary disease CA22 Phase 2 [3]
SX-682 DMHMG6X Melanoma 2C30 Phase 1 [4]
INDOPROFEN DM5QSKN Gout FA25 Withdrawn from market [2]
R-ketoprofen DMHSUQ1 N. A. N. A. Discontinued in Phase 2 [2]
2-(3-Isopropyl-phenyl)-propionic acid DMUOWNE Discovery agent N.A. Investigative [2]
2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid DMWIUR0 Discovery agent N.A. Investigative [2]
(R)-2-(4-Isobutyl-phenyl)-propionamide DMBQ0PR Discovery agent N.A. Investigative [2]
(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide DMWRIQG Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [2]
Clotrimazole DMMFCIH Cutaneous candidiasis 1F23.14 Approved [5]
Reparixin DMVBA7I Pancreatic islet transplantation failure NE84 Phase 3 [2]
SCH-527123 DMPUAOE Chronic obstructive pulmonary disease CA22 Phase 2 [6]
SB-265610 DM8TKG5 Asthma CA23 Phase 2 [7]
AZD-5069 DM3JSFK Asthma CA23 Phase 2 [8]
PS-938285 DMHZIFJ Chronic obstructive pulmonary disease CA22 Phase 2 [9]
GSK1325756 DMA6RBF Chronic obstructive pulmonary disease CA22 Phase 2 [10]
SB-656933 DMCY785 Chronic obstructive pulmonary disease CA22 Phase 2 [11]
RIST4721 DMA3DKO Hidradenitis suppurativa ED92.0 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 1 (CXCR1) TTMWT8Z CXCR1_HUMAN Agonist [1]
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Agonist [1]

References

1 Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem Biophys Res Commun. 2001 Aug 24;286(3):595-600.
2 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
5 Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
6 CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
7 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
8 Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
9 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
10 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
11 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
12 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.